Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging

a technology of therapeutic agent and modified hemoglobin, which is applied in the direction of drug composition, peptide, medical preparation, etc., can solve the problems of high cost of most therapeutic drugs and many side effects

Active Publication Date: 2014-11-13
VISION GLOBAL HLDG
View PDF9 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a hemoglobin-based therapeutic agent that targets cancer cells and efficiently kills them, providing a synergistic effect in cancer treatment. This is achieved by chemically modifying hemoglobin and linking it to therapeutic drugs. The therapeutic agent has several advantages over conventional drugs, including higher efficacy in treating tumors, lower dosage requirements, and reduced side effects. Additionally, the therapeutic agent can be used in low doses and pre-targeted to cancer cells using fluorescein molecules or other similar substances. Overall, the invention provides a novel and effective approach for treating cancer.

Problems solved by technology

Common chemotherapeutic and radiotherapeutic agents are widely used in different patients, however many side-effects are found.
Most therapeutic drugs are very expensive.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
  • Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
  • Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging

Examples

Experimental program
Comparison scheme
Effect test

example 1a

Synthesis of Ketene

[0075]To a vigorously stirred solution of 5-hexyn-1-ol (4 mmol) and triethylamine (4.5 mmol) in dichloromethane (DCM) (100 mL), methylsulfonyl chloride (MsCl) (4.1 mmol in DCM) is added dropwise at 0° C. The mixture is then warmed to room temperature for stirring overnight. Sodium bicarbonate (aqueous) is poured into the reaction mixture and the organic phase is separated. The aqueous layer is extracted with DCM and the combined organic extracts are washed with water and brine, dried over magnesium sulfate (MgSO4) and the solvent evaporated. The crude mesylate is purified by flash column chromatography (20% ethyl acetate in n-hexane) to yield colorless oil.

[0076]To a solution of mesylate (2 mmol) in acetone (60 mL), potassium iodide (2.5 mmol) is added in the reaction mixture and heated to reflux for 20 h. After cooling to room temperature, the precipitate is filtered off. The filter cake is washed with acetone (20 mL) and the solvent is evaporated. The residual o...

example 1b

Modification of Peptide and Hemoglobin Using Ketene

[0080]In a 1.0 mL eppendorf tube, peptide YTSSSKNVVR solution in water (1 mM, 10 μL), ketene (10 equivalents, 1 μL of a 100 mM stock solution of ketene in dried tetrahydrofuran), and phosphate buffer (pH 6.3 and 7.4, 80 μL) are mixed. The reaction mixture is kept at room temperature for 2 h. The conversion of the peptide is determined from total ion count of LC-MS analysis of the reaction mixtures. Using MS / MS (tandem mass spectrometry) analysis, the N-terminal selectivity is determined.

[0081]In a 1.0 mL eppendorf tube, the stabilized hemoglobin solution in buffer (1.56 mM, 40 μL), ketene (10, 20, 30, 40, and 50 equivalents, 100 mM stock solution of ketene in dried tetrahydrofuran), and phosphate buffer (pH 6.3, 7.4 and 9, 160 μL) are mixed. The reaction mixture is kept at room temperature overnight (one set at pH 9 at 37° C.). The conversions of the protein are determined from total ion count of LC-MS analysis of the reaction mixtu...

example 2a

Synthesis of Anhydride

[0082]A solution of alkyne-functionalized carboxylic acid (100 mg, 0.46 mmol), (3-dimethyl aminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (180.5 mg, 0.94 mmol), and triethylamine (0.5 mmol) in dichloromethane (20 mL) is stirred at room temperature overnight. The reaction mixture is washed with water. The organic layer is dried over anhydrous magnesium sulfate and concentrated in vacuo, and the residue is purified by flash column chromatography (eluting with 4% ethyl acetate in n-hexane) to give anhydride.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
massaaaaaaaaaa
massaaaaaaaaaa
Login to View More

Abstract

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and / or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

Description

COPYRIGHT NOTICE / PERMISSION[0001]A portion of the disclosure of this patent document contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever. The following notice applies to the processes, experiments, and data as described below and in the drawings attached hereto: Copyright © 2014, Vision Global Holdings Limited, All Rights Reserved.CROSS-REFERENCE TO RELATED APPLICATION[0002]The present application claims priority from a US provisional patent application under the Ser. No. 61 / 822,463 filed May 13, 2013, and the disclosure of which is incorporated herein by reference in its entirety.TECHNICAL FIELD[0003]The present invention describes hemoglobin-based therapeutic agent that has been chemically modified to create a material havin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/17A61K45/06A61K31/513A61K31/4188A61K51/08A61K49/00
CPCA61K38/1709A61K51/08A61K49/0017A61K31/513A61K49/0021A61K31/4188A61K45/06A61K47/6445A61K38/42A61K49/0043A61K49/0056A61K51/088A61P35/00A61P35/02
Inventor WONG, BING LOUWAI, NORMAN FUNG MANKWOK, SUI YIWONG, MAN KINMAN, CORNELIA WING YIN
Owner VISION GLOBAL HLDG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com